Related Experiment Video
Updated: Jun 14, 2025

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
Published on: March 8, 2019
Reduced hemoglobin-corrected diffusing capacity in pulmonary arterial hypertension with preserved pulmonary function
Ayako Igarashi-Sugimoto1, Ichizo Tsujino2, Hideki Shima1
1Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, N15, N7, Kita-ku, Sapporo, 060-8638, Japan.
Background:
The diffusing capacity and the transfer coefficient of the lung for carbon monoxide (DLCO and KCO, respectively) are reduced in pulmonary arterial hypertension; however, the effect of pulmonary arterial hypertension alone on these parameters and their clinical impact remain unclear. We aimed to elucidate the exclusive impact of pulmonary arterial hypertension on these two parameters and examine their association with other parameters.
Methods:
We retrospectively selected patients with pulmonary arterial hypertension with normal pulmonary function upon pulmonary function testing and with normal lung parenchyma upon chest computed tomography. We calculated the hemoglobin-corrected DLCO (DLCO-Hbc) and KCO (KCO-Hbc) and examined their association with established pulmonary hypertension-related parameters. An exploratory analysis of pulmonary vasculopathy was performed in an autopsy case.
Results:
We included 50 patients with pulmonary arterial hypertension for analysis. Their median %DLCO-Hbc and %KCO-Hbc were 62 % and 70 %, respectively. The DLCO-Hbc was associated with functional class, 6-min walk distance, alveolar-arterial oxygen tension difference, cardiac output, and pulmonary arterial hypertension-related death. The DLCO-Hbc and KCO-Hbc were also correlated with the lowest minute ventilation/carbon dioxide production ratio (ρ = -0.84 and -0.49, respectively), an index that represents ventilation-perfusion mismatch. The autopsy revealed pulmonary arterial hypertension-specific arteriopathy that was heterogeneously distributed in the lungs.
Conclusions:
The DLCO-Hbc and KCO-Hbc were reduced to 60 %-70 % in patients with pulmonary arterial hypertension even when their pulmonary function and morphology were preserved. The decreases were associated with pulmonary hypertension-related clinical parameters and survival and may be caused by heterogeneous vasculopathy and subsequent ventilation-perfusion mismatch.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Oxygen Transport in the Blood

